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ABSTRACT
Berry fruits are rich sources of polyphenolic compounds (PCs), which can
promote health benefits. Anthocyanin concentrations of red raspberry (RR)(Rubus
idaeus) extracts were determined to be a total of 887.6 ± 262.8 μg/g cyanidin-3sophoroside

(C3S) equivalents with C3S being the most prevalent. Ellagitannin

analysis by MALDI-TOF indicated sanguiin H-6 and lambertianin C were the major
ellagitannins present in RR. To explore the efficacy of RR in modulating diabetes,
seven type 2 diabetes mellitus (T2DM) and two pre-diabetic patients were given
drinks delivering one RR serving (123 g) per day in a smoothie for two weeks.
Blood samples were drawn at baseline (BSL) and post-feeding (PF) days.

The

samples were analyzed for phenolic metabolites, and for both inflammation and
insulin resistance biomarkers. Two urolithin conjugates, i.e. urolithin A glucuronide
(Uro-A glur) and urolithin A sulfate (Uro-A sulf) were found in 7 of the 9 patients’
plasma samples at nanomolar concentrations on PF day whereas anthocyaninderived

metabolites

such

as

protocatechuic

acid

(PCA)

and

3,4-

dihydroxyphenylacetic acid (DOPAC) were present at higher but not statistically
significant

levels on both groups at PF day

when compared to BSL. Results

indicated significant reductions in hsCRP (p= 0.01), and on insulin resistance where
a statistical trend on HOMA-IR (p=0.0584) for T2DM patients was seen. DOPAC, a
metabolite from anthocyanin and quercetin consumption in RR, when incubated at 1100 µM did not stimulate insulin secretion in INS-1 rat pancreatic cells. Increases
and decreases were observed on the cytokines analyzed by multiplex assay, yet,
none was significant on either group. This study demonstrates the potential of RR to
modulate levels of biomarkers of inflammation and insulin resistance in diabetic
prediabetic patients .
xiii

CHAPTER 1. LITERATURE REVIEW
1.1. Diabetes Overview
The prevalence of type 2 diabetes globally is a concern and a significant
burden due to its many health complications [1]. Diabetes is one of the most
common chronic conditions and was the seventh leading cause of death in the
United States (US) as of 2015 [2]. According to the International Diabetes
Federation, 382 million people were affected by this disease in 2013 and the
prevalence of the disease is expected to rise to 592 million by 2035 [3]. The World
Health Organization (WHO) on its 2015 report discloses that cardiovascular diseases
(CVD) are the main cause of death globally and prevalence of diabetes among
adults over 18 years of age has increased from 4.7% in 1980 to 8.5 % in 2014.
Projections indicate diabetes will still be the 7th leading cause of death in 2030 [4].
In the US, recent data indicate that 30.3 million people of all ages had the condition
in 2015 (~ 9.4 % of the population) of which 30.2 million were adults aged 18 or
older and of which 7.2 million were not aware or did not report they had diabetes [2].
An additional 84.1 million adults aged 18 years or older had prediabetes and nearly
half (48.3%) of the adults aged 65 or older were prediabetics [2]. Regardless of
technical and technological progress achieved to date, which has evolved with
therapeutic tools and public health plans, it has not been possible to stop the
progression of diabetes along with its complications [5]. Cardiovascular diseases are
the major cause of death and disability among diabetic patients [6]. Diabetic vascular
complications constitute a serious problem in diabetes which leads to additional
functional decline of different organs and cause micro- and macro-angiopathy [7].
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Diabetes as a disease has been recognized for several thousand years in
various medical systems and cultures ranging from ancient Egypt, to classical India,
China, Greece and Rome. Its meaning in Sanskrit: Madhumedha, shares the
descriptive denotation as its Latin version, diabetes mellitus, which is sweet urine. In
India, for instance, a classical diagnostic test was performed by pouring the patient’s
urine on the ground close to an ant colony and if ants swarmed the urine, the patient
was deemed a diabetic [8].
1.1.1. Diabetes Types, Etiology, and Symptoms
Diabetes mellitus is a metabolic disorder marked by elevated levels of blood
glucose

(hyperglycemia) with disturbances on carbohydrate, fat and protein

metabolism as a result of insufficient or inefficient insulin secretion, action, or both
[9, 10]. Characteristic symptoms that accompany the disease are thirst, polyuria,
blurred vision, and weight loss with severe symptoms leading to ketoacidosis or nonketotic hyperosmolar state which can derive in stupor, coma or even death when not
treated properly [10]. Based on the pathogenesis or etiology of the disease, diabetes
can be classified in type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus
(T2DM), other specific types of diabetes and gestational diabetes. T1DM makes up
5-10% of the diabetic patients [11]. It is a less common form of the disease and is
associated with autoimmune destruction of the pancreatic β-cells and therefore
complete or near-total insulin deficiency. T1DM has been further sub-classified as
Type 1A and Type 1B. Type 1A or autoimmune diabetes can sometimes be
associated with other autoimmune conditions that include Hashimoto’s thyroiditis,
Addison’s disease, vitiligo and others [12]. Because genetic factors alone do not
predict the development of type 1 diabetes, therefore, environmental factors that
may be involved include viral infections, toxins from food, cow milk intake during
2

childhood (instead of breast feeding) or vitamin D deficiency [13]. Type 1B or
idiopathic diabetes on the other side, does not present an autoimmune basis to β-cell
destruction and patients who suffer this type of diabetes are mainly of African or
Asian ancestry [11]. T2DM, on the other hand, accounts for 90-95% of diabetic
patients and its onset is dictated by a typically relative, not absolute, β-cell failure to
produce insulin. This production becomes insufficient and leads to insulin resistance.
Individuals with T1DM or T2DM have an increased risk of developing a number of
chronic diseases, which affect the heart and blood vessels, eyes, kidneys and
nerves often referred as microvascular complications. Furthermore, effects on the
heart and blood vessels can cause fatal complications such as coronary artery
disease and stroke which constitute the macrovascular complications that
accompany the disease, with cardiovascular disease being the number one cause of
death in people with diabetes mellitus [14].
Other specific types of diabetes include maturity-onset diabetes of the young
(MODY) which is characterized by early age (< 25 yrs.) onset and autosomal
dominant mode of inheritance. The cause of hyperglycemia in MODY is due to
mutations in certain genes yet insulin resistance appears to be extremely rare [15].
Six types of MODY have been described and affect specific genes such as HNF-4α,
Glucokinase, HNF-1α, IPF-1, HNF-1β, NeuroDI or BETA2 and this modality of
diabetes can encompass 2-5 % of all T2DM cases [13].
Other types of diabetes can occur due to genetic defects of insulin action, due
to diseases of the exocrine pancreas (pancreatitis, small pancreatic carcinomas) and
in patients with cystic fibrosis, diabetes is the most common comorbidity occurring in
20% of adolescents and 40–50% of adults [16]. Endocrinopathies on which
excessive production of certain hormones such as cortisol, glucagon and
3

catecholamines is present, the use of certain drugs and chemicals, i.e. rat poison,
pentamidine, glucocorticoids and infections with viruses like rubella, are among other
reasons that may cause diabetes [17, 18].
Gestational diabetes mellitus (GDM) is also a fairly common form of this
disease and it is defined as a clinical condition observed in pregnant women as a
result of insulin resistance and subsequent high blood glucose levels but also due to
prevalence of overweight and obesity in women of childbearing age [19]. This state
develops as a result of insulin action being blocked, presumably by placental
hormones [20, 21].
Normally, gestational diabetes ends after the baby is born; however, women
with gestational diabetes are at high risk of having the same condition in following
pregnancies and are at higher risk of developing T2DM later in life but risk for T1DM
is also present [22].
1.1.2. Disease Diagnosis
Several criteria can be used to diagnose whether an individual suffers from
diabetes. One of them is through hemoglobin A1c (HbA1C). HbA1C is a test that
reflects long-term blood glucose [23]. Hemolysates of red blood cells can be
chromatographed, resulting in three or more small peaks named hemoglobin A1a,
A1b, and A1c. These peaks (referred to as “fast” peaks) are eluted before the main
hemoglobin A peak, and are formed by the irreversible attachment of glucose to
hemoglobin in a two-step reaction [24]. The percentage of hemoglobin glycosylated
depends on the average glucose concentration the red cell is exposed to over time,
and due to the average 4-month life of a red cell, the percentage of glycosylated
hemoglobin indicates accurately the degree of blood sugar control over the
preceding weeks. Hemoglobin A1c is quantifiably the largest peak so that it is mostly
4

selectively measured, but occasionally all “fast" hemoglobins can be measured. An
HbA1C ≥ 6.5 % will deem a positive diagnostic for diabetes. Another way is through
plasma glucose criteria by measurement of either fasting plasma glucose (FPG) or
the 2-h plasma glucose (2-h PG) value by means of an oral glucose tolerance test
(OGTT) after taking a 75-g glucose containing drink. FPG ≥126 mg/dL (7.0 mmol/L)
or 2-h PG ≥200 mg/dL (11.1 mmol/L) during an OGTT will also indicate the person
being evaluated is indeed a diabetic [25].
“Prediabetes” is the term used for individuals with impaired fasting glucose
(IFG, defined as FPG levels 100–125 mg/dL or 5.6–6.9 mmol/L) and/or impaired
glucose tolerance (IGT, defined as 2-h PG after 75-g OGTT levels 140–199 mg/dL or
7.8–11.0 mmol/L). These conditions indicate pre-disposition for future development
of diabetes. IFG and IGT should be considered risk factors for diabetes and CVD,
and are associated with obesity, dyslipidemia (high triglycerides and/or low HDL
cholesterol), and hypertension [25], a cluster of conditions similar as those observed
on the metabolic syndrome (MS) [26]. Besides IFG and/or IGT, individuals with an
A1C of 5.7–6.4% are considered at increased risk for diabetes and CVD and should
adopt effective strategies to lower their risks [25].
1.2. Reactive Oxygen Species and Insulin Resistance
Oxidative stress and oxidative damage to tissues are a habitual result of
chronic diseases such as atherosclerosis, diabetes and rheumatoid arthritis [27].
Oxidative stress denotes an imbalance between cellular reactive oxygen species
(ROS) and antioxidants, where the former have an advantage. Examples of ROS
include the superoxide anion (•-O2), hydrogen peroxide (H2O2), hydroxyl radical
(OH), singlet oxygen (1O2) and ozone (O3). Growing evidence suggests that
oxidative stress has a causative role in insulin resistance [28]. To illustrate this, a
5

reduction on mitochondrial hydrogen peroxide emission when treating rats with a
mitochondrial-targeted antioxidant or by overexpression of catalase in mouse
skeletal muscle aided on preserving insulin sensitivity [29].
Highly reactive molecules include ROS and reactive nitrogen species (RNS).
Among these reactive molecules superoxide (•O-2), nitric oxide (•NO), and
peroxynitrite (ONOO-) are the most widely studied and are relevant in the diabetic
cardiovascular complications. Superoxide (•O-2) is produced by one electron
reduction of oxygen by different oxidases such as dihydro-nicotinamide adenine
dinucleotide

phosphate

(NADPH)

oxidase

(NOX),

xanthine

oxidases,

cyclooxygenase and also by mitochondrial electron transport chain during normal
oxidative phosphorylation, a fundamental process for generation of

adenosine

triphosphate (ATP) [30]. Five major pathways become activated because of
increased production of superoxide, all of which are involved in the pathogenesis of
diabetic complications: the polyol pathway flux, increased formation of advanced
glycation end-products (AGEs), increased expression of the receptor for AGEs and
its activating ligands, activation of protein kinase C (PKC) isoforms and over activity
of the hexosamine pathway [31].
The polyol pathway is a pathway of glucose metabolism regarded as a key
component in the pathogenesis of diabetic retinopathy, refractive changes and
cataract formation in diabetic patients [32].The enzyme aldose reductase (AR) plays
an important role in the polyol pathway as it reduces toxic aldehydes in the cell to
inactive alcohols [33]. However, when intracellular glucose concentration becomes
too high, sorbitol reduction from glucose by AR occurs as well and does this by using
NADPH as a cofactor. NADPH is an important cofactor for the regeneration of
antioxidants, and becomes reduced to glutathione (GSSG). A second enzyme,
6

sorbitol dehydrogenase oxidizes sorbitol to fructose, using nicotinamide adenine
dinucleotide (NAD+) as a cofactor [32]. Sorbitol is an alcohol that is polyhydroxylated
and strongly hydrophilic, and therefore does not diffuse easily through cell
membranes

leading

to

intracellular

accumulation

with

possible

osmotic

repercussions[34].
Advanced glycation end products (AGEs) or glycotoxins, are highly oxidant
compounds which can lead to diabetes and several other chronic diseases [35-37].
AGEs form by a nonenzymatic reaction between reducing sugars and free amino
groups of proteins, lipids, or nucleic acids, a reaction also known as the Maillard or
browning reaction [38]. Normal metabolism results in the formation of AGEs,
however, when levels become too high in tissues and the circulation, they promote
pathogenic effects through oxidative stress and inflammation. Modern diets with
abundant heat-processing result in high levels of AGEs. Dietary advanced glycation
end products (dAGEs) are recognized as a source of increased oxidant stress and
inflammation, which are directly related to the recent epidemics of diabetes and
cardiovascular disease [39]. A study with 21 patients on a high-AGE diet for 1 week
resulted in weight gain and impaired insulin sensitivity [40]. These effects happen
due to the binding of AGEs with cell surface receptors (such as the receptor of AGE,
RAGE) or cross-linking which results in a disruption of the molecular conformation of
proteins, lipids and nucleic acids and can lead to altered function [41]. Examples of
widely studied AGEs are Nε-carboxymethyllysine (CML) [42] and the very reactive
derivatives of methyl-glyoxal (MG) (i.e. hydroimidazolone) [43].
The diacylglycerol (DAG)-PKC pathway is one of the most studied pathways
in cellular signaling induced by diabetes [44]. The protein kinase C (PKC) molecule
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belongs to the serine/threonine kinase family, which catalyzes phosphorylation of
proteins involved in signal transduction. Conventional and novel PKC isoforms are
upregulated by (DAG) [45]. In diabetes, total DAG levels are elevated in vascular
tissues such as those of retina, aorta, heart and renal glomeruli, and in nonvascular
tissues such as liver and skeletal muscles, yet this is not the case in the central
nervous system and peripheral nerves [46]. In vitro studies demonstrate DAG levels
increase in a time-dependent manner as glucose levels rise from 5.5 to 22 mM in
aortic endothelial cells, retinal pericytes, smooth muscle cells and renal mesangial
cells [46].
PKC has been linked to vascular alterations which include increases in
contractility, endothelial permeability, extracellular matrix synthesis, angiogenesis,
cell growth and apoptosis, and cytokine activation and inhibition as well as leukocyte
adhesion[47].
Several groups have proposed that flux through the hexosamine synthesis
pathway (HSP) could have a role as a cellular nutrient sensor and be involved in the
development of insulin resistance and the vascular complications of diabetes [48].
The HSP is a somewhat small component of the glycolytic pathway, accounting for ~
3% of total glucose utilized [49]. The mode of action seems to be transcriptional
regulation, possibly regulated by N-acetylglucosamine in O-linkage (O-GlcNAc)
modification of transcription factors [48]. Incubation in high glucose, or with GlcNAc
or overexpression of the first and rate limiting enzyme in HSP, glutamine: fructose-6phosphate (F-6-P) amidotransferase (GFAT), enhanced the activation of the
plasminogen activator inhibitor 1 (PAI-1) promoter, as well as stimulated the cytokine
transforming growth factor beta (TGF-β) expression in mesangial cells or aortic
endothelial cells [50, 51].
8

Beta cells have a high metabolic activity due to glucose oxidation-dependent
stimulus secretion coupling, which derives in formation of ROS. With low expression
of anti-oxidative enzymes such as catalase, super oxide dismutase (SOD) and
glutathione peroxidase[52], β-cells are vulnerable to ROS and in both T1DM and
T2DM, increased ROS formation results in β-cell loss [53]. ROS involvement in the
progression of insulin resistance as well as pancreatic β-cell dysfunction has been
demonstrated [54] and it was previously reported that ROS disrupted insulin-induced
cellular redistribution of insulin receptor substrate-1 (IRS-1) and phosphatidylinositol
3-kinase (PI3-K), and thus impaired insulin-induced glucose transporter type 4
(GLUT4) translocation in 3T3-L1 adipocytes [55, 56]. Treatment with antioxidants
such as N-acetyl L-cysteine and taurine appeared to prevent hyperglycemia-induced
insulin resistance in vivo [57]. Acute and chronic administrations of the antioxidant αlipoic acid improved insulin resistance in T2DM patients, advocating a role for ROS
in the development of insulin resistance [58, 59].
1.3. Inflammation and Diabetes
Chronic inflammation is a crucial factor in the development of insulin
resistance and T2DM (6). The presence of inflammation in metabolic disorders like
diabetes mellitus has been studied in recent years and the inflammatory reaction is
mediated by acute phase proteins and cytokines. The acute phase response is a
systemic reaction to tissue injury and infection. This response leads to macrophage
release of cytokines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor
(TNF) which reach the liver and stimulate this organ to produce acute phase proteins
(APPs) [60] . The two main APPs are C-reactive protein (CRP) and serum amyloid A
(SAA) [61]. The term cytokine refers to an abundant number of cellular proteins that
mediate pleiotropic (stimulation of numerous functions on many cell types) pro9

inflammatory and anti-inflammatory effects. In the case of diabetes, the release of
such APPs and cytokines can have either diabetes-preventing or diabetes-promoting
effects [62].
A distinctive feature of T2DM is the combination of both insulin resistance and
pancreatic β-cell dysfunction, which leads to hyperglycemia at various levels. Some
mechanisms identified to contribute to this condition include oxidative stress, nuclear
factor kappa β (NF-κB) dependent production of pro-inflammatory cytokines, Toll-like
receptors {TLR (Figure 1.1.)]) expression, and inflammasome [1][63-65]. T2DM has
a genetic element but other factors such as over-nutrition (excessive food intake),
lack of physical activity, but also exogenous factors such as medications, can
intervene. Inflammatory pathways are a mean for T2DM to develop and as such,
provide an important setting to develop treatments to prevent or control diabetes.
NF-κB is considered the main control regulating the synthesis of many proteins
critical for the activation and maintenance of inflammation [9]. IL-1 is a pleiotropic
cytokine whose biologic effects include upregulated expression of adhesion
molecules, cytokines and arachidonic acid metabolites as well as enhanced
neutrophil accumulation, fibroblast proliferation and angiogenesis. The IL-1 family
consists of two pro-inflammatory cytokines: IL-1α, IL-1β and a naturally occurring
anti-inflammatory agent, the IL-1receptor antagonist (IL-1RA). IL-1β induces intra
islet inflammation which in turn diminishes β-cell function and survival and more
specifically, IL-1β plays a significant role on T2DM onset and insulin resistance [66].
TNF-α and IL-1β act as inducers of NF-kB activation producing elevated reactive
oxygen species (ROS) levels. This suggests the involvement of ROS as common
mediators of NF-kB activation [67]. Mature IL-1β is associated with the NOD
(nucleotide oligomerization domain) -like receptor pyrin domain containing protein 3
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(NLRP3) inflammasome subunit [1][68, 69]. NLRP3 is present in the pathogenesis of
T2DM, Alzheimer’s and amyotrophic lateral sclerosis [39].
Inflammation is a protective response of the host to infections and tissue
damages and includes a series of reactions such as vasodilation and recruitment of
immune cells and plasma proteins to the site of infection or injury. Reactive oxygen
species

(ROS)

generated

from

deteriorated

mitochondria

activate

NLRP3

inflammasome [70], and the latter promotes other inflammatory cytokines such as IL18 and IL-33 which are involved in the pathogenesis of diabetes [71].
1.4. Insulin Resistance and β-cell Apoptosis
Increased

insulin

resistance

(IR)

is

considered

to

be

the

major

pathophysiological cause for T2DM in patients. In healthy individuals, insulin
increases glycogen production in the liver, lipid synthesis by adipose tissue, and
glucose uptake in muscle [72].

Figure 1.1. The pro-inflammatory response of islet macrophages in type 2 diabetes.
(fig. cont’d)
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“TLR2-and TLR4-activating PAMPs (LPS, lipoproteins) and DAMPs (HSP60, HSP70,
HMGB1, hyaluronan, saturated fatty acids) are increased systemically in type 2
diabetes. Local islet-derived TLR2 and/or TLR4 DAMPs may also be increased and
may include HMGB1, necrotic cell debris and IAPP deposits. These ligands may act
on islet macrophages via TLR2 and/or TLR4, upregulating cytokine secretion (IL-6,
TNF-α), with deleterious effects on β-cell insulin secretion and α-cell glucagon
secretion. Islet-derived (IAPP, endocannabinoids) or systemically elevated (glucose,
saturated fatty acids) NLRP3 stimuli also act on macrophages to facilitate cleavage
of proIL-1β to mature IL-1β and secretion of IL-1β. IL-1β then acts in a paracrine
manner, together with elevated IL-6 and TNF-α, to impair β-cell insulin secretion and
cause dysregulated α-cell glucagon secretion. A potential role for macrophagederived IL-1α also exists but has not been studied. AP-1, activator protein 1; DC,
dendritic cell” [65].
IR is many times the result of reduced sensitivity of the insulin receptor that is
composed of two insulin-binding α-subunits and two β-subunits [73]. A reduction of
40 % β-cell mass in young adults is enough to induce hyperglycemia, a hallmark of
diabetes [74]. Problems with insulin secretion and action derive in numerous
abnormalities in T2DM such as hyperglycemia due to disruption of insulin-stimulated
glucose uptake, uncontrolled hepatic glucose production and dyslipidemia where
impaired homeostasis of fatty acids, triglycerides and lipoproteins are usually
observed [75].
Significant evidence suggests that obesity activates inflammatory signaling
pathway and can induce endoplasmic reticulum (ER) stress with particular activation
of serine/threonine kinases IκB kinase (IKK) and c-jun amino terminal kinase (JNK)
[76]. Figure 1.2., shows how IKK and JNK pathways are activated in response to
stimuli during metabolic dysregulation. This includes ligands for TNF-α, IL-1, Toll,
RAGE, ROS and ER stress, ceramide, as well as several PKC isoforms [9]. JNK
plays a central role in the cell stress response and recent evidence points at JNK1
and JNK2 isoforms as promoters of obesity and insulin resistance, whereas JNK3
activity seems to protect from excessive adiposity. Moreover, evidence indicates that
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JNK activity can promote cell tolerance to the stress associated with obesity and
type-2 diabetes in certain cell types at specific disease stages [77]. Even though IR
is characteristic of T2DM, disease progression depends on insufficient insulin
production, in all probability as result of reduced β-cell mass due to apoptosis [78].

Figure 1.2. “The insulin action can be inhibited by inflammatory signaling pathways.
Inflammation and stressful stimuli activates c-jun amino terminal kinase (JNK), IκB
kinase (IKK), and protein kinase Cθ (PKC-θ) which result in inhibition of insulin
signaling. The activation of sterol regulatory element binding protein-1c (SREBP-1C),
upstream stimulatory factor 1 (USF1), and liver X receptor (LXR) induces fatty acid
synthesis”[9].
Himsworth and Kerr were the first to recognize the relation between insulin
resistance and diabetes in 1939 based on blood glucose responses to exogenous
insulin [79]. They demonstrated that obese patients with diabetes could be classified
into two categories: those who were insulin-sensitive (T1DM) and those who were
insulin-resistant (T2DM) [79].Current information advocates at IR being an acquired
issue vastly related to unhealthy lifestyles with impaired insulin secretion being the
major genetic factor [80].
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Overweight and obesity increase risk for diabetes and CVD, mainly through IR
[81]. Weight loss has been proven beneficial in obese individuals with IR, yet, the
same benefits have not been observed in overweight individuals [81]. McLaughlin et
al. [81] administered a hypocaloric diet for 14 weeks and 2 weeks of weight
maintenance to a group of healthy volunteers with BMI 25-29.9 kg/m2. They
performed detailed metabolic phenotyping which included insulin-mediated-glucose
disposal and fasting/daylong glucose, among others. To gauge adipose cell size on
the individuals, subcutaneous fat biopsies were performed as well. The metabolic
phenotype provides a description of the metabolic state of an individual and derives
from the genetic and environmental (diet, lifestyle, gut microbial activity)
contributions under a specific set of circumstances [82]. The researchers found the
patients had weight loss (4.3 kg) which yielded significant improvements in insulin
resistance and all cardiovascular risk markers except glucose, HDL-C, and LDL-C.
They reported that insulin sensitivity was greater among those with < 2 vs > 2
cardiovascular risk factors at baseline. Decrease in adipose cell size and waist
circumference, but not weight or body fat, independently predicted improvement in
insulin resistance [81]. Their results suggested that IR overweight individuals,
regardless of the absence of potential established CVD risk markers, can yield
benefits from dietary weight loss, and that both, reduction in adipose cell size and
waist circumference, are better predictors of metabolic response than weight loss per
se [81].
There is controversy on regards to the role of factors such as obesity, insulin
resistance, insulin secretory dysfunction, and excess hepatic glucose production in
the development of T2DM. Lilioja et al. [83]

conducted a prospective study to

determine which of these factors predicted the development of the disease in a
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group of Pima Indians. The Pima Indians, a Native American population in Arizona,
have the highest reported prevalence of diabetes of any population in the world [84].
Researchers assessed potential development of the disease through oral and
intravenous glucose-tolerance tests, and a hyperinsulinemic-euglycemic clamp
study. These were performed in 200 nondiabetic Pima Indians (87 women and 113
men; mean [±SD] age, 26 ±6 years). The subjects were followed yearly thereafter for
an average of 5.3 years. Their results showed the development of diabetes in 38
subjects during follow-up. Obesity, insulin resistance (independent of obesity), and
low acute plasma insulin response to intravenous glucose (with the degree of obesity
and insulin resistance taken into account) were predictors of T2DM. The six-year
cumulative incidence of T2DM was 39 percent in persons with values below the
median for both insulin action and acute insulin response, 27 percent in those with
values below the median for insulin action but above that for acute insulin response,
13 percent in those with values above the median for insulin action and below that
for acute insulin response, and 0 in those with values originally above the median for
both characteristics. Through these results, the researchers concluded IR was a
major risk factor for the development of T2DM with low acute insulin response to
glucose being an additional but weaker risk factor [83].
Besides being a storage place for fat, adipocytes perform an important
endocrine role by secreting several relatively recently identified hormones and
cytokines [80]. These molecules are hypothesized to play relevant functions in
insulin action and metabolism of glucose and fat. The factor resistin, for instance, is
an adipocyte-secreted peptide hormone that has been observed to impair glucose
homeostasis and insulin action in rodents [85]. Work done previously shows
circulating resistin levels are increased in diabetic rodent models and that the
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administration of antiresistin antibody improves blood glucose and insulin sensitivity
[85].
Thiazolidinediones that improve insulin sensitivity reduce resistin production
[86] yet, the role of resistin in humans is not clear since reports of resistin protein
levels and gene expression in obese humans remain inconsistent [87-89].
The hormone adiponectin is another promising and interesting bridge between
IR and increased fat tissue. Studies show adiponectin plasma levels decrease
proportionally with the accumulation of adipose tissue, especially visceral one [90] as
well as with the development of insulin resistance and T2DM. Administration of
adiponectin to mice enhanced insulin sensitivity and glucose tolerance, reduced food
intake, lowered plasma glucose and triglyceride levels, and increased free fatty acids
(FFA) oxidation in muscle [91-93].
Predisposition of some individuals to IR and T2DM from birth due to
consistent IR has been found in first degree relatives and offspring of patients with
T2DM. Hence, the underlying view is that IR is at least partially determined by a role
played by genetic traits [94].

Warram et al. [95] reported that IR predicts the

development of type 2 diabetes in the offspring of diabetic parents. This is reflected
in young and healthy offspring of diabetic parents who exhibit IR and impaired
muscle insulin signaling and glycogen synthesis many years before onset of evident
T2DM [96]. Recent large-scale genome-wide association (GWA) studies, however,
have failed to detect polymorphisms of genes involved in insulin action or insulin
signaling which contribute to the development of T2DM [97]. Contrary to that, several
genes thought to be involved in the control of insulin secretion have shown
polymorphisms that grant minor but statistically significant increased susceptibility to
T2DM [97]. Therefore, reports lead to speculate that IR in offspring of diabetic
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mothers to some unknown degree may obey to the presence of obesity and/or mild
glucose intolerance during pregnancy itself, and not necessarily to genetics [98].
Vaag [98] suggests that even though many genes involved in the development of
T2DM remain to be discovered, the chance of ‘genetic insulin resistance’ due to
intrauterine programming should remain open.
Data from several sources points out that insulin-like growth factor-1 (IGF-1)
seems to play a role in progressive decline in insulin sensitivity observed in T2DM
[99]. Obese individuals display abnormalities in the growth hormone (GH)/IGF-1 axis
resulting in low basal GH levels and reduced IGF-1 levels compared with nonobese
individuals. These levels are improved when weight loss is attained [100, 101].
In higher organisms, GH controls growth by regulating IGF-1 concentrations, but
another major function of GH is to provide a mechanism for surviving periods of food
deprivation. GH stimulates lipolysis, providing FFAs and glycerol as substrates for
energy metabolism, and also inhibits insulin-induced suppression of hepatic
gluconeogenesis. These effects counteract insulin action and reduce the need for a
dietary source of carbohydrate [102].
IGF-1 shares 48% amino acid sequence identity with proinsulin. IGF-1
enhances insulin sensitivity in both experimental animals and human subjects and its
primary insulin-sensitizing action is believed to be mediated through skeletal muscle
[103]. A problem, however, when interpreting human studies of IGF-1 has been that,
in addition to enhancing insulin action, it also suppresses GH secretion.

This fact

has made difficult to determine the relative roles of the direct actions of IGF-1along
with those mediated by suppression of GH [103].
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Besides IR, defects in pancreatic β-cell function constitute one of two major
pathophysiologic abnormalities that lie behind most cases of T2DM [104]. Genetic
and epigenetic components have been identified.
While the epigenome may change due to environmental exposure, variations
may also be stable and inherited, making epigenetics a hypothetical important
pathogenic mechanism. Impaired intrauterine environment from an environment that
may alter the pancreatic islet epigenome and possibly affect β-cell function and
diabetes pathogenesis is shown in human and animal studies. Resulting low birth
weight, increased risk for postnatal metabolic disease, decreases in β-cell
proliferation mass, and insulin secretion are some documented epigenetic
modifications occurring at key β-cell genes [105, 106]. Epigenetic mechanisms
include DNA methylation and histone modifications which can be active during fetal,
postnatal and adult life [107].
Many physiologic stressors may influence β-cell function in the environment of
metabolic overload and IR commonly found in human obesity-linked T2DM.
Pathologic conditions associated with beta cell demise include ER stress, metabolic
and oxidative stress, amyloid plaques, inflammation and disruption of islet
integrity/organization (Figure 1.3.) [104].
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Figure 1.3. Stressors on the β-cell in the pathogenesis of T2DM [104].
Apoptosis or programmed cell death, is a complex biological process where
events such as cell shrinkage, chromatin condensation, DNA fragmentation and
finally disassembly into vesicles called apoptotic bodies are manifested [108].
Deposits of amyloid are characteristic of islets in T2DM [109] . These deposits are
derived from amylin or islet amyloid polypeptide (IAPP) [110]. Excess nitric oxide
(NO) production, when obtained through inducible nitric oxide synthase (iNOS), has
implications in insulin resistance, markedly when obesity is present [111]. This may
be explained by hyperglycemia and hyperlipidemia, as both conditions are common
to T2DM, and can induce iNOS expression in islet tissue in healthy animals [112].
1.5. INS-1 Cells and Insulin Secretion
Glucose represents the main physiological stimulus for the secretion of insulin
from pancreatic β-cells. As glucose enters the cells through glucose transporter 2
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(GLUT2), it becomes phosphorylated to glucose-6-phosphate by the enzyme
glucokinase and is then metabolized to generate ATP. Production of ATP induces
the closure of ATP-sensitive K+ channels (KATP) which induces membrane
depolarization and the opening of voltage-dependent Ca2+ channels (VDCCs). This
results in an increase in cellular Ca2+ influx and serves as a primary driver of the
insulin secretory mechanism [113, 114].
Insulinoma-derived INS-1 and INS-1E cells are trustworthy beta-cell
surrogates which display electrophysiological properties, secretagogue-induced
electrophysiological activity, Ca2+ signaling, stimulus-secretion coupling and
sulfonylurea and diazoxide-sensitivities similar to those found in native islets [115].
Glucose stimulated insulin secretion (GSIS) is important for the control of metabolic
fuel homeostasis and defective GSIS is a critical part of β-cell failure that leads to
T2DM [116]. Geniposide, an iridoid glucoside derived from Gardenia jasminoides or
gardenia fruit [117] was found to enhance GSIS in response to the stimulation of low
or moderately high concentrations of glucose, and promoted glucose uptake and
intracellular ATP levels in INS-1 cells. Experiments performed by Liu et al. [109]
demonstrated that geniposide modulated pyruvate carboxylase expression and the
production of intermediates of glucose metabolism suggesting this compound has
potential to improve insulin secretion in β-cells challenged by high glucose
concentrations. Kittl et al. when using quercetin to test insulin secretion on INS-1
cells [108], concluded that quercetin acutely stimulated insulin release, presumably
by short-term KATP channel inhibition and simultaneous short-term stimulation of
voltage-sensitive Ca2+ channels.
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1.6. Economic Burden of Diabetes
Diabetes along with its complications represents a substantial economic loss
to not only people who suffer from it, but also to their families, health systems and
national economies through medical costs and loss of work and wages [118]. Recent
systematic reviews estimate the world’s annual cost of diabetes to be more than US
$827 billion [119, 120]. The International Diabetes Federation (IDF) estimates that
total global health-care spending on diabetes more than tripled between 2003 to
2013 as a result of increases in the number of people with the disease and increases
in per capita diabetes spending [121]. The medical costs associated with T2DM
continue to increase and there is a dire need for new options to treat the disease.
1.7. Therapeutic Approach
The major classes of oral antidiabetic medications include biguanides such as
metformin, sulfonylureas, meglitinide, thiazolidinediones (TZD), dipeptidyl peptidase
4 (DPP-4) inhibitors, sodium-glucose cotransporter (SGLT2) inhibitors, and αglucosidase inhibitors [122]. Even though they can be effective in ameliorating
symptoms present in diabetes, a downside to these agents is that they may cause a
myriad of disturbances or side effects. These disturbances include gastrointestinal
ones such as diarrhea, nausea, and dyspepsia and may also be contraindicated in
patients with renal failure [64].
1.8. Dietary Approach
An important recommendation by the American Association of Clinical
Endocrinologists consists of consuming a plant-based diet which is high in fiber, low
in carbohydrates and calories, and high in phytochemicals/antioxidants [123].
Phenolics encompass a numerous group of natural and anthropogenic
compounds. Most natural phenolic compounds are secondary metabolites in plants
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and trees, therefore, being present in foods but are also used as supplements,
additives and nutraceuticals. Chinese physicians, for instance, have been using plant
phenolics for many years to treat various diseases and disorders. Currently, more
than 8,000 phytochemicals are known of which more than 5,000 are flavonoids.
These phytochemicals can be divided into at least 10 types depending on
their basic structure and those are: phenols, phenolic acids, hydroxycinnamic acids,
coumarins/isocoumarins, naphthoquinones, xanthones, stilbenes, anthroquinones,
flavonoids and lignins [124]. Flavonoids can further be divided into flavones,
flavonols, flavanones, flavan-3-ols, anthocyanidins and isoflavones. Phenolics are
able to act as antioxidants through several routes.
The hydroxyl groups present in phenolics are good hydrogen donors:
hydrogen-donating antioxidants, which can react with both reactive oxygen and
reactive nitrogen species [125-128]. A variety of assays can be employed to
measure the potential antioxidant and free radical scavenging capacity of
polyphenolic containing foods. Those assays include: i) oxygen radical absorbance
capacity or ORAC, which is based on hydrogen-transfer ability ii) trolox equivalent
antioxidant capacity (TEAC) a method based on the scavenging ability of
antioxidants to the long-life radical anion ABTS•+ and results from test compounds
are expressed relative to trolox, a water soluble analog of vitamin E and iii) ferric
reducing antioxidant power (FRAP) based on the ability of a compound

which

measures reduction of ferric 2,4,6-tripyridyl-s-triazine (TPTZ) to a colored product
[129].
1.8.1. Dietary Flavonoids
Flavonoids represent a large class of phenolic compounds found in numerous
food products such as fruits, vegetables, cocoa, chocolate, tea, red wine, as well as
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other plant food and beverage products [130]. The Mediterranean Diet (MD) is a diet
characterized by an abundance of vegetable foods (bread, pasta, vegetables,
legumes, fruits and nuts) where flavonoids are considered to be important bioactive
compounds which impart health benefits [131]. In terms of glucose homeostasis,
experiments performed at both in vitro and in vivo levels demonstrate they can
regulate carbohydrate digestion, insulin secretion, insulin signaling, and glucose
uptake in insulin-sensitive tissues by means of several intracellular signaling
pathways [132].
Regardless of the significant progress obtained in the fields of flavonoid
bioavailability and their effect at the cellular level, this topic remains a complex one.
Part of the problem arises from the fact that these dietary compounds are not drugs
that possess clear pharmacokinetics and pharmacological targets [133].
Flavonoids are only moderately bioavailable and highly metabolized by
intestinal, hepatic and bacterial cells and considered to be fairly reactive due to their
phenolic nuclei which grants them a reducing character as well as affinity for
proteins[133].
After the ingestion of red raspberries (RR), for instance, the polyphenols are
at least partially bioavailable to systemic organs, through absorption, distribution,
metabolism and excretion (ADME) [134]. Anthocyanins are widely reported to have
low bioavailability, with most of the studies recording peak plasma concentrations
(Cmax) ranging from 1 to 120 nmol/L [135] and urinary recoveries < 2% of intake
[136] [137]. Yet, a recent study shows extensive colonic microbiota mediated
degradation of
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C5-labeled cyanidin-3-O-glucoside which resulted in the production

of many phenolic metabolites over a 0-48 h period. The relative bioavailability of the
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C5-labeled was 6.9 % in breath as CO2, 5.4 % in urine and 32% in feces in the form

of 13C5-labeled phenolic and aromatic compounds [138] [139].
Regarding ellagitannins and ellagic acid, also very significant polyphenolics in
RR, their bioavailability is considered to be very low. These molecules are subject to
extensive metabolism by the gut microbiota to produce urolithins that are much
better absorbed. Urolithins circulate in plasma as glucuronide and sulfate conjugates
at concentrations usually ranging from 0.2–20 µM [140]. Hence, it can be implied
that the health effects of ellagitannin-containing products can be associated with
these gut-produced urolithins, therefore, evaluation of the biological effects of these
metabolites is essential [140].
Berries are distinguished from other fruits and vegetables containing
phenolics by having high concentrations of anthocyanins, with strong antioxidant
capacities, up to 4 times greater than non-berry fruits and 40 times that of cereals
[141]. Berries can be considered as small fruits that can be eaten whole and include
true berries such as black currant, red currant and gooseberry whereas false or
epigenous berries include cranberry and blueberry. RR falls within the aggregate
berries, which also include blackberry and hybrid boysenberry and the multiple berry
mulberry.
RR are becoming more appreciated due to their culinary versatility and
multiple applications [35] and are singular among berries due to their attractive red
color, low glycemic index, low caloric value, high dietary fiber, good flavor, and high
concentrations of hydrolysable and condensed tannins, flavonoids, phenolic acids,
carotenoids including lutein and zeaxanthin, choline, potassium, and vitamin C and
K1 [142]. Raspberries place very high when performing assays such as ORAC,
TEAC and FRAP on the ranking of antioxidant fruits and vegetables. This allows
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raspberries to be considered as one of the richest sources of dietary antioxidants
overall [143]. The antioxidant capacity of raspberries is believed to derive from their
vitamin C (~20%), anthocyanins (~25%) and ellagitannins (more than 50%) content
[143].
RR are native to northern North America and Eurasia. Raspberries can be
easily grown in numerous areas around the world and are relevant in both the fresh
fruit market and for processing into frozen products, juices or dried fruit. Fruits of the
raspberry tree are typically red colored but can also be black or yellow. Cultivated
RR were introduced into the United States as long ago as 1771. RR are the third
most consumed fresh berries in US households, accounting for ~ 3-4 % of total berry
production and are considered delicacies which are cultivated to deliver more than
70 million pounds per year in leading producing regions such as Washington,
Oregon and California. Raspberries can be consumed raw or as a processed
(frozen, pureed) ingredient in a number of dishes, sauces, salads, and drinks [35].
1.8.2. Phytochemical Profile of Red Raspberry
Phenolic phytochemicals are abundant in plants and serve a plethora of
biological functions such as roles in growth and development of the plant and in
defense mechanisms to counter insects and UV radiation. The phenolic profile in RR
consists mainly of anthocyanins and hydrolysable tannins. A serving of fresh RR
contained the following biologically active compounds [43]:
(A) Ellagitannins: Sanguiin H-6 and lambertianin C [144] are the major ones.
Ellagitannins (ETs) are hydrolysable tannins (HTs) which when compared to
condensed tannins are more stable [43]. Berries are considered to be the major
contributors to the ET intake in westernized countries [145]. ETs are known to be
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present in large amounts in berry fruits. Sanguiin H-6 (Figure 1.4.) is the main ET in
raspberry and strawberry [146].
Ellagitannins are capable of expressing exceptional biological activities such
as the potentiation of antibacterial activity, the inhibition of mutagenicity off
carcinogens and tumor promotion, host-mediated antitumor and highly potent
antiviral effects [147, 148].
However, the therapeutic potential of ellagitannins remains unexploited in
conventional (occidental) pharmaceutical approaches [149, 150] . In vitro, sanguiin
H-6 has been found to inhibit cell viability in a concentration-dependent manner and
it increased the rates at which MCF-7 and MDA-MB-231 human breast cancer cells
underwent apoptosis [151]. An in vitro enzymatic study by McDougall et al. [152]
strongly suggested that ellagitannins in raspberry were the main active components
for amylase inhibition, an approach considered to have the potential to be used as a
therapeutic agent to control non-insulin dependent diabetes mellitus or T2DM.
Ellagitannins are not absorbed per se but rather are subjected to the action of
colonic microbiota which yields ellagic acid which is further converted to urolithins
and the latter are absorbed into the circulatory system mainly as sulfate and
glucuronide phase II metabolites [153] [154]. Urolithins and pyrogallol deter the
formation of advanced glycation end products (AGEs) [155] which are highly
responsible for diabetes and its complications [156].
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Figure 1.4. Chemical structure of the ellagitannin Sanguiin-H6.
(B) Proanthocyanidins: Also known as condensed tannins, proanthocyanidins (PA)
are oligomeric and polymeric flavan-3-ols [157].
(C) Anthocyanins (ACN): C3S (Figure 1.5.) and cyanidin-3-glucosyl rutinoside are
the major ones [158] with some RR varieties having cyanidin-3-glucoside in
significant amounts. In general, anthocyanins with more hydroxyl groups or less
sugar moieties are considered to have greater antioxidant capacity. Alzaid et al.
[159] performed an in vitro study, which showed that acute exposure (15 min) to
berry extract (derived from blueberry, bilberry, cranberry, elderberry, raspberry seeds
and strawberry- 0.125%, w/v- the ACN content consists of cyanidins 44.5%;
delphinidins 26.1%; petunidins 14.4%; malvidins 8.9%) significantly decreased both
sodium-dependent (total uptake) and sodium-independent (facilitated uptake) [3H]D-glucose uptake in human intestinal Caco-2 cells.
In vivo in humans, raspberry ACN are metabolized into phenolic acids such as
hippuric acid, 4’-hydroxyphenylacetic acid, 3’4’-dihydroxyphenylacetic acid (DOPAC)
[160] and 4’-hydroxyhippuric acid [161]. Analyses of fecal samples collected over 24
h in human patients showed that after ingesting 140 µM of cyanidin-3-glucoside
(C3G), amounts recovered for C3G and protocatechuic acid (PCA) were 0.28 and
41.6 µmol, respectively [162].
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Figure 1.5. Chemical structure of the anthocyanin cyanidin-3-sophoroside (C3S).
PCA may help to reduce diabetes development because it can upregulate
adiponectin and GLUT4 and exert insulin-like activity by activating PPAR-γ in human
omental adipocytes [163]. When supplementing to mice at 2 % of the diet PCA
lowered levels of several markers of the disease (plasma C-reactive protein, TNF-α)
reducing diabetic complications [164].
(D) Phenolic acids: Gallic acid (GA) is the major phenolic acid in the group and is a
trihydroxybenzoic acid. Studies show GA decreases ROS in isolated mitochondria
[165] and increases antioxidant enzyme activity in a rat kidney model using diazinon
to induce renal toxicity[166]. Such enzymes include superoxide dismutases,
glutathione peroxidase (GPx), catalase, glutathione-s-transferase and reduced
glutathione (GSH). These highlights remark the potential of GA as a redox regulator.
(E) Quercetin. A flavonol being one of the most abundant polyphenols present in
fruits and vegetables [167]. The major microbial metabolite of quercetin is 3,4dihydroxyphenylacetic acid or DOPAC (Figure 1.6.) which possesses strong
antioxidant activity. DOPAC has been shown to have the highest free radical
scavenging activity when tested in vitro along with other flavonoid metabolites and it
might also reduce plasma lipid peroxidation in vivo [168, 169]. In a study using Min6
pancreatic β cells, DOPAC increased Nrf2 translocation to the nucleus and protected
pancreatic β cells against impaired insulin secretion induced by cholesterol through
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prevention of oxidative stress, apoptosis and mitochondrial dysfunction. Their
findings suggest that DOPAC is a promising drug target for the prevention of
development from a prediabetic to a diabetic state [170].

Figure 1.6. Chemical structure of 3,4-dihydroxyphenylacetic acid or DOPAC.
(F) RR also contain rheosmin or raspberry ketone (4-(4-hydroxyphenyl)-2-butanone)
which is the key flavor of raspberries and has been extensively used by the food
industry as flavoring agent and for other purposes in perfumery and cosmetics [171].
1.9. Research Objective and Specific Aims
The main objective of the clinical study proposed in this project is to
investigate the protective effect of whole red raspberries (RR) (Rubus idaeus)
against insulin resistance, oxidative stress, and biomarkers of inflammation in
prediabetic and type 2 diabetic patients. The in vitro studies will elucidate how
metabolites from the fruit can effect insulin resistance, oxidative stress and loss of
cell function. We hypothesized that regular consumption of whole RR will be effective
in improving insulin sensitivity and reducing islet cell toxicity and inflammation in
T2DM patients which often accompany this condition.
The specific aims were: (1) to determine the efficacy of whole RR against insulin
resistance and inflammation in prediabetic and T2DM patients. (2) To determine the
molecular mechanism(s) by which whole RR prevent the destruction of pancreatic βcells.
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CHAPTER 2. EFFECTS OF RED RASPBERRY POLYPHENOLS AND
METABOLITES ON BIOMARKERS OF INFLAMMATION AND
INSULIN RESISTANCE IN PREDIABETES AND TYPE 2 DIABETES
2.1 Introduction
Berry fruits are excellent sources of various polyphenolic compounds,
which exhibit anti-oxidative, anti-inflammatory and anti-carcinogenic activities
[172]. Anthocyanins and ellagitannins are the most abundant polyphenolics
found in red raspberries (RR) (Rubus idaeus) [2]. RR fruits also contain other
beneficial compounds such as vitamin C, fiber, phenolic acids and carotenoids
[172]. Anthocyanins which are responsible for the blue, purple and red color of
many plants make up the largest and probably the most important group of
water-soluble plant pigments [173]. Anthocyanins occur naturally in plants as
glycosides of the anthocyanidin molecule [174]. Multiple health-promoting
properties are attributed to anthocyanidins including antioxidant activity, antiinflammatory activity and anticarcinogenic properties, as well as protection
against heart disease, and reduction in the risk of diabetes and cognitive
function disorders [5]. Similar attributes to those of anthocyanidins have been
observed in ellagitannins and ellagic acid (a tannin and tannin derivative,
respectively) as well [175].
Diabetes mellitus (DM) which includes type 1 (T1DM) and type 2
(T2DM) is a noncommunicable and severe endocrine metabolic disorder which
reduces the ability of cells to uptake glucose and as a result induces serious
complications in various organs. Diabetes Mellitus is characterized by an
increase in blood glucose levels due to either deficiency of insulin secretion by
pancreatic β-cells or inefficiency of cells to use insulin against glucose. Type 2
diabetes (T2DM) is a serious health threat with global impact that results from
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a combination of risk factors such as genetic, environmental, and behavioral
risk factors (diet, lack of exercise) [176]. Type 2 diabetes is considered

a

chronic inflammatory disease which results in high circulating levels of tumor
necrosis factor (TNF), interleukins, and adipokines which are released from
adipose tissue [177]. Additionally, insulin resistance and dysfunctions of
pancreatic beta cells are primary characteristics of T2DM [178]. IL-1β, a key
inflammatory mediator during T2DM, promotes insulin resistance, impairs βcells function, and causes apoptosis. Reactive oxygen species (ROS) play a
pivotal role in a variety of processes such as cell proliferation, inflammation,
apoptosis, immune system and maintenance of redox balance [179]. Over
accumulation of free radicals and ROS is implicated in the development of
age-related

diseases

and

chronic

disorders

such

as

DM,

cancer,

atherosclerosis, and neurodegenerative disorders [180-182]. In a study
involving

1997

females

from

the

United

Kingdom,

higher

intake

of

anthocyanins was associated with significantly lower concentrations of highsensitivity C-reactive protein (hsCRP), a marker of obesity and diabetes [183].
Moreover, a large cohort study of 200,994 health professionals from the
United States revealed that consumption of anthocyanin-rich foods were
inversely correlated with the risk of diabetes [184]. Alzaid et al. (2013) [159]
found that acute exposure to the anthocyanin-rich extract from berry fruits
significantly decreased both Na+-dependent and Na+-independent glucose
uptake in Caco-2 cells.
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Anthocyanins are widely reported to have low bioavailability, with most
of the studies recording peak plasma concentrations (Cmax) ranging from 1 to
120 nmol/L [135] and urinary recoveries < 2% of intake [136] [137]. After the
ingestion of red raspberries, the polyphenols are partially bioavailable to
systemic organs, through absorption, distribution, metabolism and excretion
(ADME) [17].
degradation of

A recent study shows extensive colonic microbiota mediated
13

C5-labeled cyanidin-3-O-glucoside, which resulted in the

production of many phenolic metabolites over a 0-48 h period. The relative
bioavailability of the

13

C5-labeled was 6.9 % in breath as CO2, 5.4 % in urine

and 32% in feces in the form of
compounds [138] [139].

13

C5-labeled phenolic and aromatic

Ellagitannins and ellagic acid also exhibit low

bioavailability. These molecules are subject to extensive metabolism by the
gut microbiota to produce urolithins that are much more efficiently absorbed.
Urolithins circulate in plasma as glucuronide and sulfate conjugates at
concentrations usually ranging from 0.2–20 µM [140]. Hence, it can be implied
that the health effects of ellagitannin-containing products can be associated
with the gut-produced urolithins, therefore, evaluation of the biological effects
of these metabolites is essential [140].
The aim of the present work was to determine the anthocyanin profile of
mixed puree containing Meeker, Wakefield and Chemainus red raspberries, to
measure the level of metabolites in the plasma of T2DM and prediabetic
patients before and after 2 weeks of RR smoothie consumption, as well as to
measure the levels of insulin, and glucose intolerance. DOPAC, a metabolite
of quercetin and anthocyanins, was evaluated in vitro to try to elucidate
whether it can promote insulin secretion. Pro-inflammatory and anti32

inflammatory cytokines and biomarkers in the serum of the same group of
T2DM patients were measured both before and after 2 weeks consuming the
fruit.
2.2. Materials and Methods
2.2.1. Materials
Whole raspberries were provided by the National Processed Raspberry
Council

(Lynden,

WA).

Cyanidin-3-sophoroside

(C3S)

standard

was

purchased from Indofine (Hillsborough, NJ). HCYTOMAG panels for 13-plex
Luminex assay were purchased from EMD Millipore (Billerica, MA). Rat insulin
ELISA kits and oxLDL were purchased from Mercodia (Uppsala, Sweden).
Urolithin A glucuronide (Uro-A glur), isourolithin A (IsoUro-A glur),
urolithin B glucuronide (Uro-B glur), isourolithin A (IsoUro-A), urolithin A (UroA), urolithin B (Uro-B), were chemically synthesized and purified by
Villapharma Research S.L. (Parque Tecnológico de Fuente Alamo, Murcia,
Spain). Ellagic acid (EA), 3,4-Dihydroxyphenylacetic acid (DOPAC) and
protocatechuic acid (PCA)

were purchased from Sigma-Aldrich (St. Louis,

MO, USA). Urolithin A sulfate and urolithin B sulfate were obtained as
described elsewhere [185]. Stock solutions were prepared in methanol to a
final concentration of 2000 ppm (11.2 mM). All solutions were stored at −20
°C. Methanol (MeOH) and acetonitrile were purchased from J. T. Baker
(Deventer, The Netherlands). Formic acid and acetic acid were from Panreac
(Barcelona, Spain). Milli-Q system (Millipore Corp., Bedford, MA) ultrapure
water was used throughout this experiment. All chemicals and reagents were
of analytical grade.
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2.2.2. Cell Culture
Rat pancreatic β-cells (INS-1), courtesy of Dr. Henrique Cheng at the
LSU School of Veterinary Science, were used for this study. Cells were
cultured in RPMI-1640 medium (11 mM glucose and supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate and 50
µM 2-mercaptoethanol. The cells were maintained in a humidified atmosphere
(5 % CO2 at 37 ⁰C) and the experiments performed with cells between
passages 80 and 82.
2.2.3. HPLC-PDA-MS Analysis of Anthocyanins
To determine the profile and concentration of anthocyanins and
ellagitannins in liquefied RR, the method of Ludwig et al 2015 (2) was used.
Briefly, 5 g of thawed RR were homogenized with 15 ml of MeOH/H2O/formic
acid at 75:25:1 v/v/v and ultrasonicated for 1 h at 5 ºC. Samples were then
centrifuged for 10 min at 4000 x g and 20 µl of the supernatant were analyzed.
Anthocyanins were evaluated by reverse phase chromatography using a
Shimadzu UHPLC-PDA (Nexera-i LC-2040C 3D system) coupled to a
Shimadzu MS (triple-quadrupole LCMS-8040, LC-MS/MS), a Shimadzu C18
(50 x 2.1 mm, 1.9 μm) column and solvents A: 4.5% formic acid acidified water
and B: acetonitrile. Separation was achieved with a flow rate of 0.4 mL/min
and a gradient of 2% B for 0-1 min, 2-22% B from 1-11 min, 22-40% 11-12 min
at 40 °C. Twenty μL of each sample was injected for analysis. Spectral data
was collected using a photodiode array detector from 250-700 nm. Mass
spectrometry was performed under positive ion mode; data were monitored
using Q3 total ion scan (SCAN, from m/z 100-1100), and selected ion
monitoring was conducted for m/z 271, 287, 301, 303, and 331, representing
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common anthocyanidins [186]. This analysis was performed at The Ohio State
University (Columbus, OH).
2.2.4. MALDI/MS Analysis of Ellagitannins
For sanguiin H-6, the method of Kahkonen et al., 2012 [187] was used with
slight variations. Briefly, 100 g of RR was thawed, homogenized, and then mixed
with 833 ml of 70 % aqueous acetone solution. This mixture was then centrifuged at
3000 RPM for 15 min. A final volume of ~ 1,666 ml was recovered and placed on a
rotovapor at 40 ºC to evaporate the acetone portion. A ~ 540 ml volume was
recovered and freeze-dried. The ellagitannin extract was further purified using
Amberlite XAD-7 (Fischer Sci, Hampton, NH) column chromatography with 100 ml of
6% CH3CN (CH3CN:TFA:H2O 6:0.5:93.5 V/V/V) to wash out free sugars and organic
and phenolic acids.
Elution was continued with CH3CN (CH3CN: TFA 99.5:0.5) to obtain a fraction
containing flavonols, anthocyanins, and ellagitannins. To separate ellagitannins, a
column of similar size and packed with Sephadex LH-20 (GE Healthcare, Little
Chalfont, UK) (3 g) was used. The sample was introduced into the column, and
flavonols and anthocyanins were eluted with 50% MeOH. Finally, ellagitannins were
eluted with aqueous acetone (70:30 V/V). A fraction of this was used to do MALDIMS analysis.
2.2.5. Clinical Study Design
Seven type 2 diabetic (T2DM) and 2 pre-diabetic subjects on no current
diabetic treatment between the age of 18 and 70 who were not pregnant or
nursing a child were enrolled in this study at Pennington Biomedical Research
Center (PBRC). Subjects taking a medication that affects insulin sensitivity
were excluded from the study. Subjects taking any anti-inflammatory
35

medications such as naproxen, aspirin, or ibuprofen less than 2 weeks prior to
first blood test and for duration of study were excluded. Subjects with an
inflammatory disease were excluded from the study. A finger stick was done to
confirm fasting blood glucose was between 109 and 200 mg/dL to qualify, or
have a recorded post-prandial glucose greater than 200 mg/dL. The subjects
returned on day one (BSL) for an oral glucose tolerance test in which insulin
and glucose were measured at all-time points (OGTT) (0, 30, 60, 120, and 180
min), and C-reactive protein (hsCRP) levels were measured at baseline.
Insulin and hsCRP were measured from serum by chemiluminescent assays
using an Immulite® 2000 Immunoassay System (Siemens, Munich, Germany).
In an OGTT, the blood sugar rises and then returns to baseline. People with
diabetes show a slower return to baseline than people without diabetes. At
time 0 of the OGTT, 10 cc of blood were drawn and plasma frozen at -70 ºC
for analysis of metabolites. In addition, blood was drawn for a multiplex
magnetic bead-based immunoassay. The subjects returned the following day
for a blood draw. The participants were asked to come to the clinic every day
for two weeks including weekends to drink one serving (123 g) of a raspberry
smoothie containing 9.67 % erythritol as sweetener. Other than the smoothie,
no dietary changes were made. At the end of the two week feeding (PF), the
participants underwent another identical OGTT.
2.2.6. Metabolite Analysis in Plasma
Plasma samples were obtained by centrifuging whole blood at 800 x g
for 10 min at room temperature and was collected and separated into 1 ml
aliquots and placed at -80 ᵒC until use. Plasma samples were defrosted,
vortexed

and

200

µL

were

thawed
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and

extracted

with

600

µL

acetonitrile:formic acid (98:2, v/v) by vortexing for 2 min and ultrasonic bath for
10 min. Next, the mixture was centrifuged at 14000 x g for 10 min, and the
supernatant was lyophilized.
The lyophilized residue was redissolved in 100 µL of MeOH and filtered
through a 0.22 µm PVDF filter before analysis by ultra-performance liquid
chromatography
electrospray

quadrupole

ionization

time

of

flight

mass

(UPLC-ESI-QTOF-MS/MS).

spectrometry
This

analysis

using
was

performed at CEBAS-CSIC center in Murcia, Spain.
Plasma samples were analyzed using an Agilent 1290 Infinity UPLC
system coupled to the 6550 Accurate-Mass Quadrupole Time-Of-Flight
(QTOF) mass spectrometer (Agilent Technologies, Waldbronn, Germany)
through an electrospray interface with Jet Stream technology. Separation was
achieved as previously reported [188]. Briefly, a reverse phase column
Poroshell 120 EC-C18 column (3 × 100 mm, 2.7 µm) (Agilent) operating at 30
°C was used. The mobile phases were water:formic acid (99.9:0.1 v/v; Phase
A) and acetonitrile:formic acid (99.9:0.1 v/v; Phase B). Gradient was as
follows: 0–3 min, 5–15% B; 3–11 min, 15–30%; 11–15 min, 30–50%, 15–21
min, 50–90%. The flow rate was set constant at 0.4 mL/min and the injection
volume was 3 µL. The optimal conditions of the electrospray interface were as
follows: Gas temperature 280 °C; drying gas 9 L/min, nebulizer 45 psi, sheath
gas temperature 400 °C, sheath gas flow 12 L/min. Spectra were acquired in
the m/z range of 100–1100, in a negative mode and with an acquisition rate of
1.5 spectra/s. Internal mass calibration by simultaneous acquisition of
reference ions and mass drift compensation was used to obtain low mass
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errors. Data were processed using the Mass Hunter Qualitative Analysis
software (version B.06.00, Agilent).
A target screening strategy was applied to all plasma samples searching
for a list of target compounds after MS full-acquisition as well as the direct
comparison with authentic standards was performed. The quantification of
ellagitannins derived metabolites as well as DOPAC and PCA were
determined in plasma by interpolation in the calibration curve obtained with
their own available standards in the plasma matrix. All metabolites were
quantified in MS by peak area integration of its extracted ion chromatograms.
2.2.7. Effect of DOPAC on Insulin Secretion
INS-1 cells, an insulinoma cell line, were cultured following Suantawee
et al. [189] method. In brief, cells were cultured on 24-well plates at a density
of 5 X 105 cells/well. When confluency was achieved following ~ 72 h, the cells
were incubated for 30 min in modified Krebs-Ringer bicarbonate buffer (KRB)
containing 136 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2
mM MgSO4, 5 mM NaHCO3, 10 mM HEPES, 4 mM glucose, and 0.1 % bovine
serum albumin (BSA), pH 7.4. A second incubation was performed for 30 min
with KRB containing DOPAC at different concentrations (1-100 µM) or 20 mM
KCl (positive control). After incubation, the supernatant was collected and
stored frozen at -80 ⁰C for insulin determination with ELISA.
2.2.8. Analysis of Levels of Inflammatory Cytokines in Serum
The levels of pro-inflammatory and anti-inflammatory cytokines in
serum including interleukin1 beta (IL-1β), interleukin 2 (IL-2), interleukin 4 (IL4), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin
12p70

(IL-12p70),

interleukin

13

(IL-13),
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interferon

gamma

(IFN-γ),

granulocyte-macrophage

colony-stimulating

factor

(GM-CSF),

monocyte

chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 alpha
(MIP-1A), tumor necrosis factor alpha (TNF-α), and plasminogen activator
inhibitor-1 (PAI-1) were measured by a multiplex magnetic bead-based
immunoassay (Luminex®) system. This analysis was performed at PBRC
using a Luminex 200 (Luminex Co., Austin, TX).

Oxidized Low density

lipoprotein (oxLDL) was measured by ELISA using plasma.
2.2.9. Statistics
Results are expressed as means ± SD with the exception of AUC
curves for diabetics which were expressed using standard error of the mean
(S.E.M). Differences between weeks were analyzed by paired t-test whereas
levels of inflammatory cytokines in serum were analyzed using Wilcoxon
signed rank test using SAS 9.4 (SAS Institute, Cary, NC). Results for insulin
secretion were expressed as mean ±

S.E.M from two independent

experiments, each experiment having n=6. Basal control and the different
DOPAC concentrations were compared using unpaired student t-test using
GraphPad Prism v8.0 (GraphPad Software, San Diego, CA). Significance was
taken at p < 0.05.
2.3. Results
2.3.1. Quantitative Analysis of Cyanidin-3-Sophoroside (C3S) in Raspberry
Purée
C3S, an anthocyanin and one of the bioactive compounds of interest
was analyzed to determine anthocyanin profile by UHPLC-PDA-MS. C3S with
79% area under the peak (AUP), cyanidin-3-glucoside (15% AUP), and
cyanidin-3-sambubioside (4% AUP) were the major anthocyanins identified by
PDA/MS-MS data and by comparison to literature at 520 nm ([190] [191])
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(Figure 2.1.). Small traces of additional anthocyanin derivatives, tentatively
assigned identities of pelargonidin, peonidin and malvidin, accounted for the
remaining percentage area under the peak of the pigments, but were not
clearly identified due to presence of co-eluting compounds (Table 2.2.). These
peaks were assigned aglycone identities based on select ion monitoring.
Quantitative values of the anthocyanins in the extracts were calculated
after production of a standard curve using a standard of C3S as a reference
material. The curve showed a good fit by linear regression (R 2 = 0.9964) with
injections of C3S amounts of 0.1 – 10 μg. Anthocyanin concentrations of the
extracts were determined to be a total of 887.6 ± 262.8 μg/g C3S equivalents,
as determined by a HPLC calibration curve (detection at 520 nm, Table 2.2.).
The most prevalent anthocyanin of the extracts was C3S (626.0 ± 179.8 µg/g),
accounting for the majority of the total anthocyanins.
2.3.2. Qualitative Analysis of Ellagitannins in RR
Raspberry extraction of ellagitannin compounds including casuarictin (936.64
M.W.), sanguiin H-6 (1871.27 M.W.) and lambertianin C (2,805.81 M.W.) was
performed. These polyphenols are responsible for some of the beneficial health
effects in raspberry [192-194], and were analyzed by MALDI-MS. Results showed
strong peaks for two of these compounds which corresponded to sanguiin H-6
(1893.22 M.W.) being the highest followed by lambertianin C (2,827.25 M.W.)
(Figure 2.2.). Quantification of these compounds in the extract was not performed
due to lack of a standard for sanguiin H-6, therefore this analysis covered the
qualitative aspect only.
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Figure 2.1. UHPLC chromatogram of RR extract compounds, detection at 520
nm with the six peaks identified and 260-700 nm (max plot).
2.3.3. Baseline Characteristics of the Study Participants
Samples from ten patients who successfully completed the study were
collected and plasma, serum and PBMCs extracted from peripheral blood,
however one of them was determined to be a type 1 diabetic and was,
therefore, excluded from the study. Out of the 9 patients left, 7 were type 2
diabetic and 2 pre-diabetic based on their fasting glucose values during
screening. Table 2.3. lists the anthropometrics of the participants and results
observed between test day 1 (BSL) and test day 2 (PF). Values for HOMA-IR
and hsCRP decreased on PF for the type 2 diabetics after 2 weeks of feeding
with the reduction having statistical trend for HOMA-IR (p=0.0584) and
statistical significance for hsCRP (p=0.01). Values for HOMA-IR and hsCRP
numerically increased on PF in the pre-diabetic group, but with only 2 subjects
further studies are needed to judge significance.

Glucose at 0 min on the

OGTT increased in both groups, but the area under the curve (AUC) was
1,243 ± 878.97 mg/dl/minute less on PF for the type 2 diabetics and 2,497.5 ±
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1,766 mg/dl/minute less on the pre-diabetics, yet, neither difference was
significant (Figures 2.3.A and 2.3.B). AUC analysis for insulin was 1,842.3 ±
1,302.7 µU/ml/minute less on PF for the type 2 diabetics and 534.8 ± 378.1
µU/ml/minute more on the pre-diabetics, yet, neither difference

was

significant, but with a statistical trend at 0 minutes for the diabetic group
(p=0.0759) (Figures 2.3.C and 2.3.D). In the diabetic group, HOMA-IR and
hsCRP were calculated with n=7 and n=6, respectively, since one patient had
an infection and the hsCRP value was a statistical outlier. For the prediabetics, HOMA-IR and hsCRP were calculated with n=2 and n=1,
respectively, since one of the patients had a high hsCRP value, so statistical
significance could not be determined.
2.3.4. Metabolite Analysis in Plasma
Two urolithin conjugates, i.e. urolithin A glucuronide (Uro-A glur) and
urolithin A sulfate (Uro-A sulf) were identified and quantified in 7 patients (n=5
for diabetics and n=2 for pre-diabetics) at PF but not BSL, indicating they were
derived from RR smoothie feeding (Table 2.5.). Uro-A glur and Uro-A sulfate
were quantified after consumption at PF in the range of high and low nM
range, respectively (Table 2.5.). Uro-A sulfoglucuronide was also identified but
not quantified, (because no standard was available), in the samples PF of 6
subjects (n=5, diabetics and n=1, prediabetic).
In these patients no other urolithin conjugates such as Uro-B or IsoUroA glur were found suggesting a metabolism of ellagitannins according to their
metabotype A

[195]. Therefore, among 9 patients, IsoUro-A glur and its

sulfate derivate were identified and quantified in only one of the diabetic
patients, suggesting metabolism of ellagitannins according to their metabotype
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B [195]. Uro-B sulfate was also identified in the PF samples of this diabetic
patient. Finally, no urolithin conjugates were identified in a different diabetic
patient; however, dimethyl ellagic acid (DMEA) glucuronide was identified but
not quantified in this patient suggesting a lack of metabolism of ellagitannins
(metabotype 0). DMEA glucuronide was also found in the PF samples of one
of the pre-diabetic patients.
All urolithin conjugates were quantified above the limits of detection
(LOD) and quantification (LOQ) previously reported in García-Villalba et al.
[196]. Moreover, high concentration (low µM range) of DOPAC and PCA were
identified and quantified in all volunteers of both BSL and PF samples (before
and after RR intake, respectively). However, no significant differences were
found over the course of the study. Figure 2.5. shows structures for the
metabolites found at highest concentrations.
2.3.5. DOPAC and Insulin Secretion
Incubation with KRB containing DOPAC from 1-100 µM did not stimulate
insulin secretion from INS-1 cells. Decreases were observed on all treatments
with those at 1 and 3 µM not being significant, yet those at 10, 30 and 100 µM
had statistically significant decreases (Figure 2.6.). The only significant
increase was elicited by 20 mM KCl (positive control) with a 2.6-fold increase
over basal.
2.3.6. Levels of Inflammatory Cytokines in Serum
Table 2.6. lists results for multiplex magnetic bead-based immunoassay.
Levels on 7 cytokines (IL-1β, IL-2, IL-4, IL-6, IL-12p70, IL-13, and GM-CSF)
were not determined as they were beneath the LOD. Increases and decreases
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were observed on the rest of cytokines analyzed on both T2DM and prediabetic patients but none were statistically significant.
2.4. Discussion
The quantification of total ACN in the RR purée extract yielded 88.8 ±
26.3 mg/100g of fresh fruit of which 91.9% or 81.7 ± 23.7 mg/100 g
corresponded to cyanidin-based ACN content. This is in agreement with Wu et
al. [197] who found 90.2 ± 19.2 mg/100 g cyanidin-based ACN content and
total ACN of 92.1 ± 19.7 mg/100 g when measuring ACNs in 5 different RR
samples by means of HPLC-DAD-ESI/MS/MS. The high standard deviation
observed could be explained by potential heterogeneous distribution of the 3
varieties that constituted the analyzed sample.

Sanguiin H-6

Lambertianin C

Figure 2.2. Results for ellagitannin extract using MALDI-TOF. Major peaks
corresponded to sanguiin H-6 (1893.22 M.W.) and lambertianin C (2,827.25 M.W.).
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Table 2.1. Concentration (µg/g of C3S equivalent) of anthocyanins in red raspberry
extract identified and quantified by UHPLC-PDA-QQQ.
Peak
Identity
m/z
Mean (µg/g)
Per serving (123 g)
1 Cyanidin-3-sophoroside

611/287

626.0 ± 179.8

77.0 ± 22.1 mg

2 Cyanidin-3-glucoside

449/271

143.2 ± 44.8

17.6 ± 5.5 mg

3 Cyanidin-3-sambubioside

581/287

44.1 ± 13.0

5.4 ± 1.6 mg

4 Pelargonidin-derivative

595/271

23.8 ± 8.5

2.9 ± 1.0 mg

5 Peonidin-derivative

301

24.2 ± 8.3

3.0 ± 1.0 mg

6 Malvidin-derivative

301

26.3 ± 8.4

3.2 ± 1.0 mg

Total anthocyanins

887.6 ± 262.8

Values are means ± SD, n=3
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109.1 ± 32.2 mg

Table 2.2. Results for baseline and post-feeding characteristics of the study participants.
Type 2 Diabetics (n=7)

Prediabetics (n=2) **

Race (African American/Caucasian) n/n

3/4

1/1

Gender (male/female) n/n

2/5

0/2

Age, y

60.9 ± 9.0

63.0

103.0 ± 16.2

101.1

37.2 ± 6.3

38.6

Systolic blood pressure, mm Hg

132.6 ± 11.3

124.5

Diastolic blood pressure, mm Hg

86.7 ± 8.2

71.0

Fasting glucose, mg/dL

170.0 ± 27.8

109.0

Body weight, kg
BMI, kg/m2

OGTT glucose (time 0), mg/dL

BSL: 161.6 ± 32.0 PF: 164.0 ± 38.5

BSL: 93.0 PF: 100.0

HOMA-IR

BSL: 13.3 ± 7.3

PF: 9.4 ± 5.4

BSL: 6.0

PF: 8.5

hsCRP, mg/L (n=6, T2DM and n=1, PD) BSL: 4.9 ± 2.0

PF: 4.0 ± 1.6*

BSL: 5.6

PF: 6.1

All results are expressed as the mean ± SD. Statistical analyses were performed using a paired t-test to detect differences between
BSL and PF. OGTT, oral glucose tolerance test; HOMA-IR, homeostasis model of assessment of insulin resistance; hsCRP, high
sensitivity C-reactive protein. HOMA index was calculated with the formula: HOMA= [serum glucose levels (mg/dl) X insulin levels
(µU/ml)/22.5. * p = 0.01. ** No statistics done due to small numbers.
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Figure 2.3. Effects of RR smoothie consumption on blood glucose and insulin levels
after oral glucose tolerance test on day 1 (BSL) and day 2 (PF). Results are
expressed as the mean ± S.E.M. Statistical analyses were performed using paired ttest. (A) Glucose tolerance test curve for T2 diabetic patients (n=7). (B) Glucose
tolerance test curve for pre-diabetic patients (n=2). (C) Glucose tolerance test curve
for insulin in T2 diabetic patients (n=7). (D) Glucose tolerance test curve for insulin in
pre-diabetic patients (n=2). * No statistics done due to small numbers.
Because PBMCs contain several key inflammatory cells, higher levels of
insulin resistance and inflammatory biomarkers at the baseline for T2 diabetic
and pre-diabetic patients were expected to be present.
IR constitutes a crucial factor in the development of type 2 diabetes
along with hypertension

and cardiovascular (CV) disease [198]. Results

indicated significant (inflammatory biomarker such as hsCRP) and non-significant
reductions (glucose AUC, insulin resistance through HOMA-IR) after two weeks of
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RR smoothie consumption. Stull et al. [199] found that consuming a smoothie
containing blueberries for 6 weeks had a greater increase in insulin sensitivity in
obese and insulin-resistant adults (prediabetics, accounting for 67%) when
compared to individuals that consumed a placebo smoothie (41%) and was
measured by a 10 % or greater favorable change in insulin sensitivity. For this study
researchers used the hyperinsulinemic-euglycemic clamp (HEC) to assess insulin
sensitivity. Even though HEC is considered the “gold standard”, HOMA-IR has
proved to be a powerful proxy to assess IR [200, 201]. In our study, HOMA-IR had a
p value of 0.0584 resulting in a statistical trend but not statistical significance. AUC
analysis for both glucose and insulin showed decreases on PF day, but these were
not statistically significant on either group. Losso et. al [202] reported that one
feeding of two slices of fenugreek enriched bread (5%) to a group of eight T2DM
patients yielded a significant reduction in AUC for insulin when compared to bread
with no fenugreek fed to the same group. RR constitutes a high source of fiber
providing 8 g per 123 g of fruit [145]. Zhao et al. 2018 [203] identified short chain
fatty acid (SCFA) - producing bacterial strains who were promoted by dietary fibers.
In their study, most other potential producers were present at either decreasing or
not changing numbers in patients with T2DM. Researchers found that when the
fiber-promoted SCFA producers were present in higher number, participants had
better improvement in hemoglobin A1c levels. This was attributed in part due to
increased glucagon-like peptide-1 production. SCFAs such as acetate and butyrate
have demonstrated the ability to improve glucose homeostasis through production of
glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), which can stimulate insulin
secretion [204-206].
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However, based on the results obtained through HOMA-IR in the present
study, insulin secretion in patients was reduced favoring an insulin sensitivity effect.
This finding could indicate this insulin sensitivity effect could be elicited by other
molecule in the fruit or perhaps, other metabolite(s).
Serum concentration of CRP is increased in both impaired glucose tolerance
(IGT) and T2DM [207, 208]. Based on numerous studies, minor CRP elevation
(hsCRP) has been shown to be associated with future major CV risk (hsCRP: <1
mg/L = low risk; 1–3 mg/L = intermediate risk; 3–10 mg/L =high risk; >10 mg/L _=
unspecific elevation) [209]. A decrease from 4.9 ± 2 on BSL to 4.0 ± 1.6 on PF was
registered in our study and found to have statistical significance on T2DM patients
(p= 0.01).
The metabolite analysis found two urolithin conjugates, i.e. urolithin A
glucuronide (Uro-A glur) and urolithin A sulfate (Uro-A sulf) which were found
in 7 of the 9 patients’ (both groups) samples, but only for PF indicating they
were derived from RR smoothie feeding. These were metabolites from the
ellagitannin portion of the fruit, whereas anthocyanin-derived metabolites such
as DOPAC and PCA were present at similar concentrations on BSL and PF
suggesting these metabolites might have come from different dietary sources
as well.
An increase in IL-10 after two weeks of raspberry consumption was
expected

but

cytokine

analysis

by

multiplex

magnetic

bead-based

immunoassay found the opposite. Increases and decreases were observed on
the rest of cytokines analyzed, yet, none of these changes were statistically
significant.
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Interpatient variability was observed in plasma metabolite analysis as
well as for other biomarkers and this could be due to differences in diets,
individual microbiota or potential effects of erythritol used as non-caloric
sweetener.
From the 9 patients evaluated in the study, six presented a urolithin
metabotype (UM) A (urolithin A producers only), two (men both) a UM-B
(production of urolithin A, isourolithin A and/or urolithin B) and one a UM-0
(urolithin non-producers). Cortés-Martín et al. [210] proposed that aging is the
main factor affecting the distribution of urolithin metabotypes when they
evaluated a cohort of n=839, from 5-90 yrs of age. Besides this, the
researchers described a progressive increase for UM-B parallel to a decrease
in UM-A, especially for individuals aged 20-40, and when considering a group
of n=23 patients aged 30-63 who suffered from metabolic syndrome, both UMA and UM-B had a similar share.

In the present study, however, the

dominating UM was UM-A, therefore, it is important to highlight their cohort
consisted mainly of caucasian individuals only whereas in the present study
African
(56%)

Americans constituted 44.4 % of the patients evaluated, the rest
being

Caucasian.

Gonzalez-Sarrías

et

al.[211]

observed

that

overweight–obese individuals with UM-B were at higher CVD risk than those
with UM-A or UM-0, hence, the UM-A preponderance among the patients from
our clinical trial could be taken as a positive outcome.
Regarding potential mechanisms of anti-diabetic properties of whole RR
observed in patients from the clinical trial, Edirisinghe & Freeman [212], list two ways
these can be addressed: insulin dependent and insulin independent. Within insulin
dependent, an insulin sensitivity enhancement was observed judging by the drop on
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insulin and hsCRP, an important biomarker of inflammation and CVD risk [213].
Assessment of the metabolite DOPAC (1-100 µM) to investigate if it could elicit
insulin secretion on INS-1 cells showed the opposite, an even had a toxic
effect at higher concentrations. This finding is congruent with what was
observed on the clinical trial patients as insulin and glucose levels dropped by
PF day indicating an improvement in insulin sensitivity. Work by other
researchers has demonstrated stimulation on insulin secretion by compounds
such as quercetin [115, 214] and cyanidin [189] when used at levels ranging
from 20-100 µM. These concentrations, however, may not be feasible at
physiological levels due to metabolic availability and toxicological issues.
Researchers described activation of the extracellular signal-regulated
kinase (ERK) 1/2 pathway and L-type voltage-dependent Ca2+ channel
(VDCC) in INS-1 cells as responsible for increases in insulin secretion. For the
insulin independent part, both inhibition of digestive enzymes involved in
carbohydrate breakdown as well as inhibition of glucose absorption in the GI tract
can be present, however in the present study a minor increase in glucose from
OGTT at 0 min on PF was observed yet non-significant reductions on the AUC for
OGTT on both T2DM and prediabetics were present on PF. Work performed by
other researchers highlights these findings.
Edirisinghe & Freeman, found when overweight adults were fed a
freeze-dried strawberry powder that it significantly reduced postprandial insulin
response and reduced postprandial inflammatory response (IL-6 and hsCRP)
when the participants ate a high carbohydrate and high fat meal (P < 0.05)
[212]. Alzaid et al., 2013 [159] used a berry extract containing raspberry seed
and were able to significantly decrease both sodium-dependent intestinal cell
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(total uptake) and sodium-independent [3H]-D-glucose uptake in human
intestinal Caco-2 cells. Treatment for 16 h showed SGLT1 mRNA and GLUT2
mRNA expression was significantly reduced (P < 0.05.) Moreover, McDougall
et al. [215] observed amylase was inhibited when performing an in vitro
enzymatic study using raspberry. They concluded that ellagitannins in
raspberry were the main agents for this inhibition, which indicates these
polyphenols in RR can promote beneficial effects just like the anthocyanin
fraction does.
2.5. Conclusion
Two urolithin conjugates, (Uro-A glur and Uro-A sulf) were found in 7 of
the 9 patients’ plasma samples at nanomolar concentrations (1.3 - 63.2 ± 31.2
nM,

Table

2.5.),

whereas

anthocyanin-derived

metabolites

such

as

protocatechuic acid (PCA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were
present at micromolar concentrations yet at similar levels on BSL (PCA= 0.5 ±
0.14, DOPAC= 1.4 ± 0.28) and PF (PCA=0.6 ± 0.07, DOPAC= 1.7 ± 0.8).
Other metabolites were present in only some of the patients, illustrating that
each individual’s microbiome, ethnicity, age, etc., most likely plays a role on
the outcome of such metabolites. Results indicated a significant reduction in
hsCRP (BSL: 4.9 ± 2.0, PF: 4.0 ± 1.6 (p=0.01)) which is a very important
biomarker of inflammation and heart disease risk. A reduction showed only a
statistical trend for HOMA-IR when evaluating for IR. DOPAC, a metabolite
from anthocyanin and quercetin in RR, when incubated at 1-100 µM did not
stimulate insulin secretion in INS-1 cells. A longer feeding period with a larger
group is recommended to test if the effects observed can be improved. This
study demonstrated the potential of RR to modulate levels of biomarkers of
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inflammation and insulin resistance in T2DM patients most likely through
antioxidant activity from the polyphenolics present and from anti-diabetic
effects through insulin dependent mechanisms.
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Table 2.3. Results from plasma analysis for raspberry metabolites by UPLC-ESI-QTOF-MS/MS
Uro-A-Glur α Uro-A-Sulf α Iso-Uro-A α Iso-Uro-A Sulf α Uro-B- Sulf α

PCAb

DOPACb

Diabetics (n=7)
BSL

--63.2 ± 31.2d

PF

--7 ± 4.2d

---

---

37.4 ± 1.1f

11.1 ± 0.6f

--1.6 ± 0.7f

0.6 ± 0.4c

1.2 ± 0.5c

0.6 ± 0.4c

1.1 ± 0.6c

Pre-diabetics (n=2)*
BSL

--10.3e

PF

---

---

---

---

0.4e

1.6e

1.3e

---

---

---

0.5e

2.2e

All results are expressed as mean ± SD. Uro-A-Glur, urolithin-A-glucuronide; Uro-A-Sulf, urolithin-A-sulfate; Iso-Uro-A, isourolithinA-glucuronide; Iso-Uro-A Sulf, isourolithin-A-sulfate; Uro-B- Sulf, urolithin-B-sulfate; PCA, protocatechuic acid (3,4-ihydroxybenzoic
α
b
c
d
acid); DOPAC, 3,4-dihydroxyphenyl acetic acid. , nanomolar; , micromolar; ---, not detected; , detected in n=7; , detected in
e

f

n=5; , detected in n=2; , detected in n=1. Compounds urolithin-A- sulfoglucuronide (n=5, diabetics and n=1 pre-diabetics] and
dimethyl ellagic acid (n=1 for both diabetics and pre-diabetics ; both not listed in the table) were detected but not quantified on the
PF day. * No statistics done due to small numbers.

.
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Table 2.4. Serum and plasma biomarkers results (pg/ml) by multiplex magnetic bead-based immunoassay and ELISA.
IL-8

IL-10

IFN-γ

TNF-α

MCP-1

MIP-1α

PAI-1

oxLDL β

Diabetics (n=7)
BSL

7.5 ± 2.9

8.1 ± 5.3

7.8 ± 4.3

15.9 ± 1.4

783.7 ± 211.3

PF

7.7 ± 2.3

7.5 ± 4.1

7.7 ± 3.3

15.4 ± 1.3

827.6 ± 282.4

3.8 ± 0.7
4.2 ± 0.7

132.7 ± 20.7

75.4 ± 19.7

133.1 ± 32.2

78.1 ± 20.2

Pre-diabetics (n=2)*
BSL
PF

17.8
14.9

8.3

11.9 #

13.4

1148.5

19

126.7

43.8

7.9

8.2 #

11.6

1054.5

17.8

103.2
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All results are expressed as mean ± SD. Data was analyzed using Wilcoxon signed rank test. #, n=1; β, oxLDL assay performed
through ELISA using plasma samples. * No statistics done due to small numbers.
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Figure 2.4. Structures of most abundant metabolites from both ellagitannins and
anthocyanins in RR found in the plasma of clinical trial participants after 2 weeks of
smoothie feeding.
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Figure 2.5. Treatment of INS-1 cells with 1-100 uM DOPAC. Results are expressed
as mean ± S.E.M. from two independent experiments, each experiment having n=6;
* p < 0.05 when compared with basal.
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CHAPTER 3. CONCLUSIONS AND FUTURE WORK
It has been well established that edible berries are an excellent source of various
polyphenolic

compounds,

which

exhibit

anti-oxidative,

anti-inflammatory

and

anticarcinogenic activities [172]. The purpose of this study was to evaluate the potential
of whole RR to modulate IR and inflammation in T2DM patients. Results from the
clinical trial showed a significant downregulation of hsCRP, an important biomarker of
inflammation and CV risk, and an improvement on insulin sensitivity based on HOMA-IR
results which showed a statistical trend. These results confirm the potential that RR has
to modulate IR and inflammation and we hypothesize that a longer feeding period may
yield better and more representative results that could lead to further downregulation of
both IR and inflammation biomarkers in T2DM patients. A trial involving more patients is
recommendable too as a larger sample size would be more representative of the effects
RR consumption may have and would better evaluate interpatient variability that is
normally observed in clinical studies of this kind. Another aim was to determine the
molecular mechanism(s) by which whole RR prevent the destruction of pancreatic βcells. To determine if DOPAC, a metabolite of anthocyanin and quercetin, had insulin
secretion effects in vitro, an ELISA for insulin secretion using rat pancreatic β-cells (INS1) showed DOPAC did not stimulate insulin secretion at physiologically observed
concentrations or even at higher non-physiological concentrations. An assay evaluating
human β-cells is recommended to confirm these results. However, this finding
complements the insulin sensitivity improvement rather than insulin secretion
enhancement found in the patients from the clinical trial. It is possible that this effect of
insulin sensitivity improvement may have derived from other molecules present in RR.
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For instance ellagitannins, which were not evaluated in the present study due to
lack of proper standards for sanguiin H-6, the major ellagitannin present in RR may
have played a role The major ellagitannin-derived metabolites found in plasma of
patients such as Uro-A-glur and Uro-A- sulf could have also played a role.
Therefore, studies that evaluate the effect(s) of these particular compounds may
help elucidate the exact mechanism(s) being triggered to yield insulin sensitivity
improvement through RR consumption.

59

REFERENCES
1.
Lee, H.M., et al., Upregulated NLRP3 inflammasome activation in patients with
type 2 diabetes. Diabetes, 2013. 62(1): p. 194-204.
2.
Ishimoto, H., et al., In vivo anti-inflammatory and antioxidant properties of
ellagitannin metabolite urolithin A. Bioorganic & Medicinal Chemistry Letters, 2011.
21(19): p. 5901-5904.
3.
Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to
start. Nat Rev Drug Discov, 2014. 13(6): p. 465-76.
4.
Noratto, G.D., B.P. Chew, and L.M. Atienza, Red raspberry (Rubus idaeus L.)
intake decreases oxidative stress in obese diabetic (db/db) mice. Food Chem, 2017.
227: p. 305-314.
5.
Dal, S. and S. Sigrist, The Protective Effect of Antioxidants Consumption on
Diabetes and Vascular Complications. Diseases, 2016. 4(3).
6.
Orasanu, G. and J. Plutzky, The Continuum of Diabetic Vascular Disease: From
Macro- to Micro. Journal of the American College of Cardiology, 2009. 53(5 Suppl): p.
S35-S42.
7.
Rosolova, H., et al., [Macrovascular and microvascular complications in type 2
diabetes patients]. Vnitr Lek, 2008. 54(3): p. 229-37.
8.
Battle, J., Translating Sweetness: Type 2 Diabetes, Race, Research, and
Outreach (Doctoral Dissertation). 2012.
9.
Hajiaghaalipour, F., M. Khalilpourfarshbafi, and A. Arya, Modulation of glucose
transporter protein by dietary flavonoids in type 2 diabetes mellitus. Int J Biol Sci, 2015.
11(5): p. 508-24.
10.
Alberti, K.G.M.M. and P.Z. Zimmet, Definition, diagnosis and classification of
diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes
mellitus. Provisional report of a WHO Consultation. Diabetic Medicine, 1998. 15(7): p.
539-553.
11.
American Diabetes, A., Diagnosis and classification of diabetes mellitus.
Diabetes Care, 2011. 34 Suppl 1: p. S62-9.
12.
Diabetes: An Old disease, a New Insight Springer series: Advances in
Experimental Medicine and Biology., ed. S.I. Ahmad. 2013: Landes Bioscience I
Springer Science+ Business Media LLC dual imprint.

60

13.
Phlips, J.C. and R.P. Radermecker, [Type 1 diabetes: from genetic predisposition
to hypothetical environmental triggers]. Rev Med Liege, 2012. 67(5-6): p. 319-25.
14.
Grundy, S.M., et al., Diabetes and cardiovascular disease: a statement for
healthcare professionals from the American Heart Association. Circulation, 1999.
100(10): p. 1134-46.
15.
Fajans, S.S., G.I. Bell, and K.S. Polonsky, Molecular mechanisms and clinical
pathophysiology of maturity-onset diabetes of the young. N Engl J Med, 2001. 345(13):
p. 971-80.
16.
Moran, A., et al., Cystic fibrosis-related diabetes: current trends in prevalence,
incidence, and mortality. Diabetes Care, 2009. 32(9): p. 1626-31.
17.
Pandit, M.K., et al., Drug-induced disorders of glucose tolerance. Ann Intern
Med, 1993. 118(7): p. 529-39.
18.
Forrest, J., M. Menser, and J.A. Burgess, HIGH FREQUENCY OF DIABETES
MELLITUS IN YOUNG ADULTS WITH CONGENITAL RUBELLA. The Lancet, 1971.
298(7720): p. 332-334.
19.
Kampmann, U., et al., Gestational diabetes: A clinical update. World J Diabetes,
2015. 6(8): p. 1065-72.
20.
Catalano, P.M., et al., Longitudinal changes in insulin release and insulin
resistance in nonobese pregnant women. American Journal of Obstetrics &
Gynecology, 1991. 165(6): p. 1667-1672.
21.
Sivan, E., et al., Longitudinal study of carbohydrate metabolism in healthy obese
pregnant women. Diabetes Care, 1997. 20(9): p. 1470-5.
22.
Nilsson, C., Gestational Diabetes Mellitus- Future risk for mother and child., in
Medicine 2013, Lund.
23.
Florkowski, C., HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the
Evidence. The Clinical biochemist. Reviews, 2013. 34(2): p. 75-83.
24.
JM, M., Blood Glucose, in Clinical Methods: The History, Physical, and
Laboratory Examinations., H.W. Walker HK, Hurst JW, Editor. 1990, Butterworths:
Boston.
25.
2. Classification and
38(Supplement 1): p. S8-S16.

Diagnosis

of

Diabetes.

Diabetes

Care,

2015.

26.
Kaur, J., A comprehensive review on metabolic syndrome. Cardiology research
and practice, 2014. 2014: p. 943162-943162.

61

27.
Baynes, J.W. and S.R. Thorpe, Role of oxidative stress in diabetic complications:
a new perspective on an old paradigm. Diabetes, 1999. 48(1): p. 1-9.
28.
Onyango, A.N., The Contribution of Singlet Oxygen to Insulin Resistance.
Oxidative Medicine and Cellular Longevity, 2017. 2017: p. 14.
29.
Anderson, E.J., et al., Mitochondrial H2O2 emission and cellular redox state link
excess fat intake to insulin resistance in both rodents and humans. The Journal of
Clinical Investigation, 2009. 119(3): p. 573-581.
30.
Evans, J.L., et al., Are Oxidative Stress−Activated Signaling Pathways Mediators
of Insulin Resistance and β-Cell Dysfunction? Diabetes, 2003. 52(1): p. 1-8.
31.
Giacco, F. and M. Brownlee, Oxidative stress and diabetic complications.
Circulation research, 2010. 107(9): p. 1058-1070.
32.
Mathebula, S.D., Polyol pathway:
complications in the eye. 2015, 2015. 74(1).

A

possible

mechanism

of

diabetes

33.
Brownlee, M., Biochemistry and molecular cell biology of diabetic complications.
Nature, 2001. 414(6865): p. 813-20.
34.
Gabbay, K.H., The sorbitol pathway and the complications of diabetes. N Engl J
Med, 1973. 288(16): p. 831-6.
35.
Tamanna, N. and N. Mahmood, Food Processing and Maillard Reaction
Products: Effect on Human Health and Nutrition. International Journal of Food Science,
2015. 2015: p. 6.
36.
Friedman, M., Prevention of adverse effects of food browning. Adv Exp Med Biol,
1991. 289: p. 171-215.
37.
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